Show simple item record

dc.creatorSavale, Laurent
dc.creatorHuitema, Marloes
dc.creatorShlobin, Oksana
dc.creatorKouranos, Vasilis
dc.creatorNathan, Steven D.
dc.creatorNunes, Hiliaro
dc.creatorGupta, Rohit
dc.creatorGrutters, Jan C.
dc.creatorCulver, Daniel A.
dc.creatorPost, Marco C.
dc.creatorOuellette, Daniel
dc.creatorLower, Elyse E.
dc.creatorAl-Hakim, Tamara
dc.creatorWells, Athol U.
dc.creatorHumbert, Marc
dc.creatorBaughman, Robert P.
dc.date.accessioned2023-12-21T19:36:54Z
dc.date.available2023-12-21T19:36:54Z
dc.date.issued2022-02-09
dc.identifier.citationWASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension Laurent Savale, Marloes Huitema, Oksana Shlobin, Vasilis Kouranos, Steven D. Nathan, Hiliaro Nunes, Rohit Gupta, Jan C. Grutters, Daniel A. Culver, Marco C. Post, Daniel Ouellette, Elyse E. Lower, Tamara Al-Hakim, Athol U Wells, Marc Humbert, Robert P. Baughman European Respiratory Review Mar 2022, 31 (163) 210165; DOI: 10.1183/16000617.0165-2021
dc.identifier.issn1600-0617
dc.identifier.urihttp://hdl.handle.net/20.500.12613/9351
dc.description.abstractSarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This includes the results of two large SAPH-specific registries. A task force was established by the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) to summarise the current level of knowledge in the area and provide guidance for the management of patients. A group of sarcoidosis and pulmonary hypertension experts participated in this task force. The committee developed a consensus regarding initial screening including who should undergo more specific testing with echocardiogram. Based on the results, the committee agreed upon who should undergo right-heart catheterisation and how to interpret the results. The committee felt there was no specific phenotype of a SAPH patient in whom pulmonary hypertension-specific therapy could be definitively recommended. They recommended that treatment decisions be made jointly with a sarcoidosis and pulmonary hypertension expert. The committee recognised that there were significant defects in the current knowledge regarding SAPH, but felt the statement would be useful in directing future studies.
dc.format.extent17 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartEuropean Respiratory Review, Vol. 63, No. 163
dc.relation.isreferencedbyEuropean Respiratory Society (ERS)
dc.rightsAttribution-NonCommercial CC BY-NC
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleWASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension
dc.typeText
dc.type.genreJournal article
dc.description.departmentThoracic Medicine and Surgery
dc.relation.doihttp://dx.doi.org/10.1183/16000617.0165-2021
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeLewis Katz School of Medicine
dc.creator.orcidGupta|0000-0002-8764-6538
dc.temple.creatorGupta, Rohit
refterms.dateFOA2023-12-21T19:36:54Z


Files in this item

Thumbnail
Name:
GuptaEtAl-JournalArticle-2022- ...
Size:
841.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial CC BY-NC
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC